Advances in Cancer Therapy: New Findings from Malaysia, South Korea, and Yugoslavia

Strategic Insights -

Researchers from Malaysia, South Korea, and Yugoslavia have made significant progress in cancer therapy, specifically in the treatment of non-small cell lung cancer (NSCLC). Three studies published in prominent medical journals have evaluated the efficacy and toxicity of various combinations of chemotherapy and radiotherapy regimens. The findings suggest that certain treatments may be effective in improving survival rates and reducing toxicity in patients with advanced NSCLC.

Key Takeaways:

  • A study from Malaysia found that gemcitabine and carboplatin combination chemotherapy was effective in treating locally advanced and metastatic NSCLC, with a 57% response rate and a median survival of 9 months.
  • Researchers in South Korea conducted a Phase II trial investigating the efficacy of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin. The study reported a 72.5% objective tumor response rate and a median survival of 23.2 months.
  • A phase II study in Yugoslavia examined the feasibility and activity of concurrent hyperfractionated radiotherapy (Hfx RT) and low-dose carboplatin/paclitaxel in patients with early-stage NSCLC. The study found a 52% complete response rate and a median survival of 35 months.

Statistics:

  • 57% response rate to gemcitabine and carboplatin combination chemotherapy in Malaysia (Leow et al., 2005)
  • 72.5% objective tumor response rate to induction chemotherapy with gemcitabine and vinorelbine in South Korea (Lee et al., 2005)
  • 52% complete response rate to concurrent Hfx RT and low-dose carboplatin/paclitaxel in Yugoslavia (Jeremic et al., 2005)
  • Median survival time of:

+ 9 months in Malaysia (Leow et al., 2005)

+ 23.2 months in South Korea (Lee et al., 2005)

+ 35 months in Yugoslavia (Jeremic et al., 2005)

Sources:

  • Leow, C. H., et al. (2005). Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer. Respirology, 10(5), 629-635.
  • Lee, D. H., et al. (2005). Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4), 1037-1044.
  • Jeremic, B., et al. (2005). Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: Long-term results of a phase II study. J Clin Oncol, 23(28), 6873-6880.